Med Gen and Tru-Vantage marketed and sold a product called Snorenz, a product to be sprayed on the back of the throat to reduce or prevent snoring for 6 to 8 hours. The FTC brought a complaint, alleging that Med Gen and Tru-Vantage had no reasonable basis for the claims, and that Med Gen and Tru-Vantage failed to state that Snorenz did not treat sleep apnea and they failed to advise users of the severity of sleep apnea and the need for a physician consolation.

Full case and case summary also available online at: http://www.mlmlegal.com/legal-cases/Snorenz.php